Use of rupatadine in the manufacture of pharmaceutical composition for treating chronic obstructive pulmonary disease

• US 9,241,936 B2
• Filed: 05/18/2012
• Issued: 01/26/2016
• Est. Priority Date: 03/06/2012
• Status: Expired due to Fees

• Current Assignee: Beijing Weifeng Yimin Bio-Technology Limited Company
• Original Assignee: Beijing Weifeng Yimin Bio-Technology Limited Company
• Inventors: Hu, Zhuowei
• Primary Examiner(s): SHIAO, REI TSANG
• Application Number:
  US14/383,459
• Publication Number:
  US 20150018382A1
• Time in Patent Office: 1,348 Days
• Field of Search: 514/290, 514/168, 514/560, 514/547
• US Class Current: 1/1
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed is the use of rupatadine in the manufacture of pharmaceutical composition for preventing or treating chronic obstructive bronchitis, obstructive emphysema or chronic obstructive pulmonary disease. The new medicament, i.e. rupatadine, for treating chronic obstructive pulmonary disease is obvious in therapeutic effects, and low in toxic and side effects, and safe in use in the aspects of treating chronic obstructive bronchitis, obstructive emphysema or chronic obstructive pulmonary disease.

Claims

1. A method of preventing or treating chronic obstructive bronchitis, obstructive emphysema or chronic obstructive pulmonary disease in a subject in need thereof, comprising:

administering to the subject an effective amount of at least one active ingredient selected from the group consisting of rupatadine and a pharmaceutically acceptable derivative of rupatadine, the at least one active ingredient being provided in a pharmaceutical composition free of active ingredients other than rupatadine and its pharmaceutical acceptable derivative.

2. The method according to claim 1, wherein the pharmaceutically acceptable derivative is a pharmaceutically acceptable salt or ester of rupatadine.

3. The method according to claim 1, wherein the pharmaceutical composition comprises the at least one active ingredient and a pharmaceutically acceptable carrier.

4. The method according to claim 3, wherein the pharmaceutical composition comprises 0.1%-99% of the at least one active ingredient and 0.1%-99% of the carrier, the percentage is a mass percentage of each component to the total mass of the pharmaceutical composition.

5. The method according to claim 1, wherein the pharmaceutical composition is administered orally, intravenously, intramuscularly, intradermally or hypodermically.

6. The method according to claim 1, wherein the pharmaceutical composition is selected from an aqueous solution, a non-aqueous solution, and a suspension.

7. The method according to claim 3, wherein the pharmaceutical composition consists essentially of the pharmaceutically acceptable carrier and an effective amount of the at least one active ingredient.

8. The method according to claim 3, wherein the pharmaceutical composition consists of the pharmaceutically acceptable carrier and an effective amount of the at least one active ingredient.

9. The method according to claim 7, wherein the method consists essentially of administering to the subject the pharmaceutical composition.

10. The method according to claim 9, wherein the pharmaceutical composition consists of the pharmaceutically acceptable carrier and an effective amount of the at least one active ingredient.

11. The method according to claim 9, wherein the method consists of administering to the subject the pharmaceutical composition.

12. The method according to claim 11, wherein the pharmaceutical composition consists of the pharmaceutically acceptable carrier and an effective amount of the at least one active ingredient.

13. The method according to claim 1, wherein chronic obstructive bronchitis, obstructive emphysema or chronic obstructive pulmonary disease is treated in the method.

14. The method according to claim 3, wherein the method consists essentially of administering to the subject the pharmaceutical composition.

15. The method according to claim 3, wherein the method consists of administering to the subject the pharmaceutical composition.